LivaNova plc Stock
LivaNova plc Stock
We can see a decrease in the price for LivaNova plc. Compared to yesterday it has lost -€1.000 (-1.750%).
With 9 Buy predictions and not the single Sell prediction the community is currently very high on LivaNova plc.
As a result the target price of 66 € shows a slightly positive potential of 17.86% compared to the current price of 56.0 € for LivaNova plc.
Pros and Cons of LivaNova plc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Cons
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of LivaNova plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| LivaNova plc | -1.750% | -3.448% | 14.286% | 31.455% | 19.658% | -18.841% | -13.178% |
| Neogen Corp. | 3.540% | 2.632% | -3.306% | -22.517% | -36.066% | -69.412% | -56.294% |
| Bio-Rad Labs Inc. A | 0.960% | 10.817% | -2.227% | -21.197% | -5.790% | -44.234% | - |
| Merit Medical Systems | 2.700% | 3.401% | 13.433% | -1.299% | 11.765% | 54.472% | 53.241% |
Comments
LivaNova PLC (NASDAQ: LIVN) had its price target raised by analysts at Mizuho from $75.00 to $80.00. They now have a "buy" rating on the stock.
Show more
Ratings data for LIVN provided by MarketBeat
LivaNova PLC (NASDAQ: LIVN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Show more
Ratings data for LIVN provided by MarketBeat
LivaNova PLC (NASDAQ: LIVN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for LIVN provided by MarketBeat
News
LivaNova Reports First-Quarter 2024 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings
LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that its wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a